Derivation of a comprehensive semi-empirical proton RBE model from published experimental cell survival data collected in the PIDE database

Front Oncol. 2024 Nov 27:14:1415213. doi: 10.3389/fonc.2024.1415213. eCollection 2024.

Abstract

We aimed to develop a comprehensive proton relative biological effectiveness (RBE) model based on accumulated cell survival data in the literature. Our approach includes four major components: (1) Eligible cell survival data with various linear energy transfers (LETs) in the Particle Irradiation Data Ensemble (PIDE) database (72 datasets in four cell lines); (2) a cell survival model based on Poisson equation, with α and β defined as the ability to generate and repair damage, respectively, to replace the classic linear-quadratic model for fitting the cell survival data; (3) hypothetical linear relations of α and β on LET, or α ( L E T ) α x = α α + b α L E T and β ( L E T ) β x = α β - b β L E T ; and (4) a multi-curve fitting (MCF) approach to fit all cell survival data into the survival model and derive the aα , bα , aβ , and bβ values for each cell line. Dependences of these parameters on cell type were thus determined and finally a comprehensive RBE model was derived. MCF showed that (aα , bα , aβ , bβ ) = (1.09, 0.0010, 0.96, 0.033), (1.10, 0.0015, 1.03, 0.023), (1.12, 0.0025, 0.99, 0.0085), and (1.17, 0.0025, 0.99, 0.013) for the four cell lines, respectively. Thus, aα = 1.12 ± 0.04, bα = 0.0019 ± 0.0008, aβ = 0.99 ± 0.03, and bβ = 0.013 ∗ αx , and approximately α 1.12 α x and β = ( 0.99 - 0.013 α x L E T ) β x . Consequently, a relatively reliable and comprehensive RBE model with dependence on LET, αx , βx , and dose per fraction was finally derived for potential clinical application.

Keywords: cell survival model; linear energy transfer (LET); multiple curve fitting (MCF); proton therapy; relative biological effectiveness (RBE).

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.